Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/GSK716155> ?p ?o }
Showing triples 1 to 71 of
71
with 100 triples per page.
- GSK716155 abstract "GSK716155 (Albugon) is a recombinant human glucagon-like peptide (GLP)-1-Albumin protein created using Human Genome Sciences' proprietary albumin fusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein (GLP-1)[1]. It is an agonist of the Glucagon-like Peptide-1 Receptor (GLP1R) and underwent clinical drug trials for treatment of Type 2 Diabetes Mellitus. The fusing of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of therapeutically active proteins in the body[1].".
- GSK716155 wikiPageExternalLink index.html.
- GSK716155 wikiPageExternalLink NCT00354536.
- GSK716155 wikiPageID "17380296".
- GSK716155 wikiPageLength "6345".
- GSK716155 wikiPageOutDegree "35".
- GSK716155 wikiPageRevisionID "596579489".
- GSK716155 wikiPageWikiLink 7TM.
- GSK716155 wikiPageWikiLink Adenylate_cyclase.
- GSK716155 wikiPageWikiLink Adenylyl_cyclase.
- GSK716155 wikiPageWikiLink Agonist.
- GSK716155 wikiPageWikiLink Albumin.
- GSK716155 wikiPageWikiLink Anorectic.
- GSK716155 wikiPageWikiLink Apoptosis.
- GSK716155 wikiPageWikiLink Beta_cell.
- GSK716155 wikiPageWikiLink Beta_cells.
- GSK716155 wikiPageWikiLink Category:Anti-diabetic_drugs.
- GSK716155 wikiPageWikiLink Category:Diabetes.
- GSK716155 wikiPageWikiLink Clinical_trial.
- GSK716155 wikiPageWikiLink Cyclic_adenosine_monophosphate.
- GSK716155 wikiPageWikiLink Diabetes_mellitus_type_2.
- GSK716155 wikiPageWikiLink Drug_trial.
- GSK716155 wikiPageWikiLink GLP-1.
- GSK716155 wikiPageWikiLink GLP1R.
- GSK716155 wikiPageWikiLink G_protein–coupled_receptor.
- GSK716155 wikiPageWikiLink Glucagon.
- GSK716155 wikiPageWikiLink Glucagon-like_peptide-1.
- GSK716155 wikiPageWikiLink Glucagon-like_peptide_1_receptor.
- GSK716155 wikiPageWikiLink Half-life.
- GSK716155 wikiPageWikiLink Human_Genome_Sciences.
- GSK716155 wikiPageWikiLink Hunger_(motivational_state).
- GSK716155 wikiPageWikiLink Incretin.
- GSK716155 wikiPageWikiLink Incretins.
- GSK716155 wikiPageWikiLink Insulin.
- GSK716155 wikiPageWikiLink MAPK.
- GSK716155 wikiPageWikiLink MEK.
- GSK716155 wikiPageWikiLink Mitogen-activated_protein_kinase.
- GSK716155 wikiPageWikiLink Neogenesis.
- GSK716155 wikiPageWikiLink Peptide.
- GSK716155 wikiPageWikiLink Phospholipase.
- GSK716155 wikiPageWikiLink Protein.
- GSK716155 wikiPageWikiLink Protein_Kinase_A.
- GSK716155 wikiPageWikiLink Protein_Kinase_C.
- GSK716155 wikiPageWikiLink Protein_kinase_A.
- GSK716155 wikiPageWikiLink Protein_kinase_C.
- GSK716155 wikiPageWikiLink Raf.
- GSK716155 wikiPageWikiLink Ras_subfamily.
- GSK716155 wikiPageWikiLink Recombinant_DNA.
- GSK716155 wikiPageWikiLink Royal_Air_Force.
- GSK716155 wikiPageWikiLink Satiety.
- GSK716155 wikiPageWikiLink Type_2_Diabetes.
- GSK716155 wikiPageWikiLinkText "GSK716155".
- GSK716155 hasPhotoCollection GSK716155.
- GSK716155 wikiPageUsesTemplate Template:Citation.
- GSK716155 wikiPageUsesTemplate Template:Multiple_issues.
- GSK716155 subject Category:Anti-diabetic_drugs.
- GSK716155 subject Category:Diabetes.
- GSK716155 hypernym Protein.
- GSK716155 type Article.
- GSK716155 type Drug.
- GSK716155 type Protein.
- GSK716155 type Article.
- GSK716155 type Diabete.
- GSK716155 type Drug.
- GSK716155 comment "GSK716155 (Albugon) is a recombinant human glucagon-like peptide (GLP)-1-Albumin protein created using Human Genome Sciences' proprietary albumin fusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein (GLP-1)[1]. It is an agonist of the Glucagon-like Peptide-1 Receptor (GLP1R) and underwent clinical drug trials for treatment of Type 2 Diabetes Mellitus.".
- GSK716155 label "GSK716155".
- GSK716155 sameAs m.043p7px.
- GSK716155 sameAs Q5514567.
- GSK716155 sameAs Q5514567.
- GSK716155 wasDerivedFrom GSK716155?oldid=596579489.
- GSK716155 isPrimaryTopicOf GSK716155.